The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

John F. R. Robertson

Royal Derby Hospital

Derby

UK

[email]@nottingham.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Royal Derby Hospital, Derby, UK. 2013
  • Division of Breast Surgery, Graduate Entry Medicine & Health School (GEMS), University of Nottingham, Royal Derby Hospital, UK. 2012
  • University of Nottingham, Nottingham City Hospital, Nottingham, UK. 2001 - 2010
  • Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Rd, United Kingdom. 2009
  • Professional Unit of Surgery, City Hospital, Nottingham, UK. 1999 - 2005

References

  1. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Robertson, J.F., Ferrero, J.M., Bourgeois, H., Kennecke, H., de Boer, R.H., Jacot, W., McGreivy, J., Suzuki, S., Zhu, M., McCaffery, I., Loh, E., Gansert, J.L., Kaufman, P.A. Lancet Oncol. (2013) [Pubmed]
  2. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Robertson, J.F., Lindemann, J.P., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., Ellis, M.J. Breast Cancer Res. Treat. (2012) [Pubmed]
  3. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Robertson, J.F., Steger, G.G., Neven, P., Barni, S., Gieseking, F., Nolè, F., Pritchard, K.I., O'Malley, F.P., Simon, S.D., Kaufman, B., Petruzelka, L. Ann. Oncol. (2010) [Pubmed]
  4. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. Robertson, J.F., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., Ellis, M.J. J. Clin. Oncol. (2009) [Pubmed]
  5. Fulvestrant (Faslodex) -- how to make a good drug better. Robertson, J.F. Oncologist (2007) [Pubmed]
  6. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Robertson, J.F., Semiglazov, V., Nemsadze, G., Dzagnidze, G., Janjalia, M., Nicholson, R.I., Gee, J.M., Armstrong, J. Eur. J. Cancer (2007) [Pubmed]
  7. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Robertson, J.F., Come, S.E., Jones, S.E., Beex, L., Kaufmann, M., Makris, A., Nortier, J.W., Possinger, K., Rutqvist, L.E. Eur. J. Cancer (2005) [Pubmed]
  8. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Robertson, J.F., Howell, A., Gorbunova, V.A., Watanabe, T., Pienkowski, T., Lichinitser, M.R. Breast Cancer Res. Treat. (2005) [Pubmed]
  9. Fulvestrant: pharmacokinetics and pharmacology. Robertson, J.F., Harrison, M. Br. J. Cancer (2004) [Pubmed]
  10. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Robertson, J.F. Cancer Treat. Rev. (2004) [Pubmed]
  11. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Robertson, J.F., Blamey, R.W. Eur. J. Cancer (2003) [Pubmed]
  12. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer. Robertson, J.F., Odling-Smee, W., Holcombe, C., Kohlhardt, S.R., Harrison, M.P. Clin. Ther (2003) [Pubmed]
  13. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Robertson, J.F., Osborne, C.K., Howell, A., Jones, S.E., Mauriac, L., Ellis, M., Kleeberg, U.R., Come, S.E., Vergote, I., Gertler, S., Buzdar, A., Webster, A., Morris, C. Cancer (2003) [Pubmed]
  14. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. Robertson, J.F., Harrison, M.P. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  15. The Internet: the future source of information for professionals in the field of breast cancer. Robertson, J.F. Breast (2002) [Pubmed]
  16. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer. Robertson, J.F. J. Steroid Biochem. Mol. Biol. (2001) [Pubmed]
  17. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Robertson, J.F., Jaeger, W., Syzmendera, J.J., Selby, C., Coleman, R., Howell, A., Winstanley, J., Jonssen, P.E., Bombardieri, E., Sainsbury, J.R., Gronberg, H., Kumpulainen, E., Blamey, R.W. Eur. J. Cancer (1999) [Pubmed]
  18. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Robertson, J.F., Willsher, P.C., Winterbottom, L., Blamey, R.W., Thorpe, S. Eur. J. Cancer (1999) [Pubmed]
  19. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Robertson, J.F., Howell, A., Buzdar, A., von Euler, M., Lee, D. Breast Cancer Res. Treat. (1999) [Pubmed]
 
WikiGenes - Universities